

## CERTIFICATE OF ANALYSIS

<b>Product Name</b>	Cagrilintide (TFA removed), Cat.#: 319572
<b>Lot No.</b>	MTFA31217-0407
<b>Sequence</b>	{Eicosanedioic acid- $\gamma$ -Glu}- KC*NTATC*ATQRLAEFLRHSSNFGPILPPTNVGSNTP-NH2 (Acetate Salt)
<b>Dissolution condition</b>	100%H2O
<b>Length</b>	38AA
<b>Modification</b>	Disulfide bridge: Cys3-Cys8; acetate salt
<b>Molecular Weight (MW)</b>	4409.01
<b>Storage</b>	-20°C

Test Items	Specifications	Results
MW by MS	4409.60	Conforms
Purity by HPLC	>95%	95.200%
Peptide content	N/A	N/A
Moisture content	N/A	N/A
Acetic acid content	N/A	N/A
Appearance	White to off-white lyophilized powder	Conforms
Quantity	500mg	5.0mg*100

NovoPro Bioscience Inc. (hereafter NovoPro) warrants material of said quality at the time of sale. It is the sole responsibility of the customers to determine the adequacy of all materials for any intended or specific purpose or use. NovoPro's sole obligation is to replace the material up to the extent of the purchase price. This warranty applies only to products in original packaging and does not apply to a product which has been tampered with or altered in any way in or which has been misused or damaged by accident or negligence. All claims must be received writing (by fax or email) within 30 days from date when product arrive at the destination city and failure to do so shall constitute a waiver by customers for any and all such claims.

Certified by:



Quality Assurance Department

Apr/25/2024




Sample Information

Order ID :MTFA31217  
 Name :Cagrilintide  
 Sequence :{Eicosanedioic acid- $\gamma$ -Glu}-KC\*NTATC\*ATQRLAEFLRHSSN  
 NFGPILPPTNVGSNTP-NH2 (Acetate Salt)  
 Lot. No :MTFA31217-0407  
 Pump A :0.1%Trifluoroacetic in 100% water  
 Pump B :0.1%Trifluoroacetic in 100% acetonitrile  
 Total Flow :1ml/min  
 Wavelength :214nm  
 Analytical column type :Phenomenex Luna® 5  $\mu$ m C18(2) (4.6\*250mm\*5  $\mu$ m)  
 Dissolution method :100%H2O  
 Inj. Volume : 50ul

Time	Module	Action	Value
0.01	Pumps	B.Conc	30
30.00	Pumps	B.Conc	60
33.00	Pumps	B.Conc	100
38.00	Pumps	B.Conc	100
40.00	Pumps	B.Conc	30
50.00	Controller	Stop	


Chromatogram



Peak Table

Detector A 214nm

Peak#	Ret. Time	Area	Height	Area%
1	17.492	16117	1494	0.124
2	18.646	214805	14743	1.659
3	18.890	12326491	936861	95.200
4	19.271	390635	10351	3.017
Total		12948047	963449	100.000



### Sample Information

Dissolution method	:15% ACN+85% H <sub>2</sub> O	Interface	:ESI	Prerod Bias	:+4.5kv
Date Acquired	:2024/04/23 15:02:15	Nebulizing Gas Flow	:1.50L/min	Detector	:-0.2kv
Injection Volume	:0.2ul	CDL Temp	:250°C	T.Flow	:0.2ml/min
Block Temp	:200	CDL Volt	:0v	B.conc	:50% H <sub>2</sub> O/50% MEOH

Order ID	:MTFA31217
Name	:Cagrilintide
Sequence	:{Eicosanedioic acid- $\gamma$ -Glu}-KC*NTATC*ATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH <sub>2</sub> (Acetate Salt)
Lot.No	:MTFA31217-0407
Theoretical	:4409.01
Observed	:4409.60

## Instructions for dissolving Cagrilintide

The Cagrilintide is soluble in 100% H<sub>2</sub>O or 1xPBS. The maximum concentration is 5.0 mg/ml.

The steps are as below:

1. Adding 1.0 ml ultrapure water to the 2.0 ml tube of Cagrilintide;
2. Wait about 1 minute at room temperature until the solution is clear, which indicates the peptide is fully dissolved;
3. Use a sterile 0.22  $\mu$ m membrane filter for a particle-free and bacteria-free Cagrilintide solution.

For example, Catalog# SLGPR33RB, Millipore Millex-GP Syringe Filter Unit, 0.22  $\mu$ m, polyethersulfone, 33 mm, gamma sterilized.

The detailed application information of Cagrilintide can be found at:

<https://pubmed.ncbi.nlm.nih.gov/37364590/>

Frias, Juan P et al. "Efficacy and safety of co-administered once-weekly cagrilintide 2· 4 mg with once-weekly semaglutide 2· 4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial." *Lancet* (London, England) vol. 402,10403 (2023): 720-730.  
doi:10.1016/S0140-6736(23)01163-7